Efficacy of Ofatumumab and Teriflunomide in Patients with Relapsing MS from Racial/Ethnic Minority Groups: ASCLEPIOS I/II Subgroup Analyses

Medicine, Rheumatology and Immunology, Neurology,
Ofatumumab   Teriflunomide   Relapsing Multiple Sclerosis   Racial/Ethnic Minority Groups   ASCLEPIOS Trials   No Evidence of Disease Activity  

Academic Paper Report Academic Background Multiple Sclerosis (MS) is an inflammatory disease of the central nervous system characterized by the destruction of myelin and axons, leading to neurological dysfunction and progressive disability. It is estimated that there are approximately 2.8 million MS patients worldwide, with over 700,000 affected in...